Annovis Bio closed at $1.21 on Nov 4, up 11.01%, 76.3% below its 52-week closing high. Volume of 1.4M shares was 1.68× its 20-day average (above normal).
Split-adjusted performance: +2.5% over one month, -49.6% over six months, -40.1% over one year.
Short interest was 5.7M shares at the Oct 15 settlement, down 3.0% from the prior report (15.3% of float, 8.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio | $1.21 | +11.01% | −49.6% | — | — | — | $51.6M | |
| IBIOiBio | $0.8000 | −2.85% | −54.8% | −100.0% | — | — | $51.4M | Compare |
| PLRXPliant Therapeutics | $0.8518 | −1.03% | −30.7% | — | — | — | $52.7M | Compare |
| HOWLWerewolf Therapeutics | $1.09 | +1.87% | +67.6% | — | 17.5% | — | $53.0M | Compare |
| OSTXOS Therapies Incorporated | $1.15 | −0.86% | −33.5% | — | — | — | $53.8M | Compare |
| CNTBConnect Biopharma Holdings Limited | $0.7805 | +0.83% | −68.5% | +5666.7% | −624.4% | — | $49.2M | Compare |
| TLPHTalphera | $1.05 | +0.96% | +20.7% | — | — | — | $54.5M | Compare |
| GANXGain Therapeutics | $1.11 | −3.48% | −41.9% | — | — | — | $48.4M | Compare |
| BOLDBoundless Bio | $2.40 | +0.84% | +51.9% | — | — | — | $55.5M | Compare |
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
